DekaBank Deutsche Girozentrale raised its stake in Medicines (NASDAQ:MDCO) by 26.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 39,900 shares of the company’s stock after purchasing an additional 8,400 shares during the period. DekaBank Deutsche Girozentrale owned 0.05% of Medicines worth $1,332,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently bought and sold shares of the company. SG Americas Securities LLC grew its stake in Medicines by 33.8% in the fourth quarter. SG Americas Securities LLC now owns 7,145 shares of the company’s stock valued at $195,000 after purchasing an additional 1,805 shares during the last quarter. Jane Street Group LLC purchased a new position in Medicines in the fourth quarter valued at about $202,000. Elkfork Partners LLC purchased a new position in Medicines in the fourth quarter valued at about $214,000. Xact Kapitalforvaltning AB purchased a new position in Medicines in the fourth quarter valued at about $218,000. Finally, Nisa Investment Advisors LLC grew its stake in Medicines by 27.1% in the fourth quarter. Nisa Investment Advisors LLC now owns 10,780 shares of the company’s stock valued at $295,000 after purchasing an additional 2,300 shares during the last quarter.
Shares of Medicines opened at $32.20 on Friday, according to Marketbeat.com. The company has a debt-to-equity ratio of 9.70, a current ratio of 2.56 and a quick ratio of 2.52. The stock has a market capitalization of $2.36 billion, a price-to-earnings ratio of -3.83 and a beta of 0.67. Medicines has a fifty-two week low of $31.57 and a fifty-two week high of $32.21.
Several equities analysts have issued reports on the company. BidaskClub lowered Medicines from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 24th. JPMorgan Chase reiterated an “overweight” rating and issued a $45.00 target price on shares of Medicines in a research note on Wednesday, January 24th. Oppenheimer set a $50.00 target price on Medicines and gave the company a “buy” rating in a research note on Monday, March 12th. Chardan Capital reiterated a “buy” rating and issued a $85.00 target price on shares of Medicines in a research note on Wednesday, January 24th. Finally, Zacks Investment Research lowered Medicines from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. Medicines currently has a consensus rating of “Buy” and a consensus price target of $50.00.
In other Medicines news, Director Armin M. Kessler sold 20,000 shares of the firm’s stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $28.71, for a total value of $574,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director William Crouse sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, March 21st. The stock was sold at an average price of $32.26, for a total value of $241,950.00. Following the completion of the sale, the director now directly owns 60,633 shares of the company’s stock, valued at approximately $1,956,020.58. The disclosure for this sale can be found here. 8.22% of the stock is currently owned by company insiders.
Medicines Company Profile
The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.
Receive News & Ratings for Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicines and related companies with MarketBeat.com's FREE daily email newsletter.